

Birinapant

Catalog No: tcsc1719



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1260251-31-7

Formula:

$C_{42}H_{56}F_2N_8O_6$

Pathway:

Apoptosis

Target:

IAP

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 40 mg/mL (49.57 mM); H₂O :

Alternative Names:

TL32711

Observed Molecular Weight:


806.94

Product Description

Birinapant a bivalent Smac mimetic, is a potent antagonist for **XIAP** and **cIAP1** with **K_d** values of 45 nM and IC50 & Target: Kd: 45 nM (XIAP),

In Vitro: Birinapant causes significant degradation of cIAP1 and 2. Birinapant + TRAIL-treated cells show increased levels of active caspase-8 and caspase-3, as well as PARP cleavage, over single agents within 4 h of treatment, indicative of apoptosis-mediated cell death. Birinapan significantly decreases the viability of SUM190 cells in a dose-dependent manner. Birinapant treatment in the XIAP knockdown cell line (SUM190 shXIAP) causes an overall reduction in viability at lower doses (30-300 nM)^[1]. Birinapant causes apoptosis in the sensitive cells. Birinapant in combination with TNF-α, causes PARP cleavage in 451Lu and WM1366 cell lines^[2]. Birinapant induces time-course of caspase-3 activation in HCT116 human colon carcinoma and MDA-MB-231 human breast adenocarcinoma cells^[3].

In Vivo: Birinapant can inhibit tumor growth in melanoma xenotransplantation models. Staining for activated caspase-3 in biopsies of the same tumors show a modest increase in apoptotic cells in the birinapant treated animals^[2]. Birinapant (15 mg/kg, i.p.) induces apoptosis in HCT116 tumor-bearing mouse^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!